• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

黎巴嫩一家三级医疗中心耐万古霉素肠球菌感染的临床表现、特征及结局:一项病例-病例对照研究

Clinical manifestations, characteristics, and outcome of infections caused by vancomycin-resistant enterococci at a tertiary care center in Lebanon: A case-case-control study.

作者信息

Abi Frem Jim, Ghanem Marwan, Doumat George, Kanafani Zeina A

机构信息

Brighton and Sussex University Hospitals, Brighton, United Kingdom.

American University of Beirut, Beirut, Lebanon.

出版信息

J Infect Public Health. 2023 May;16(5):741-745. doi: 10.1016/j.jiph.2023.02.023. Epub 2023 Mar 6.

DOI:10.1016/j.jiph.2023.02.023
PMID:36958169
Abstract

BACKGROUND

Vancomycin-resistant enterococci (VRE) are prevalent infectious agents that particularly affect critically-ill patients, and they are on the rise in Lebanon. We aim at determining the potential risk factors and complications for VRE and vancomycin-susceptible enterococci (VSE) infections in a hospital setting and identify risk factors for in-hospital mortality.

METHODS

A case-case-control study design was used where patients with VRE and VSE were included as two separate groups and each group was compared to uninfected controls. We also constructed binary regression models to detect risk factors that were associated with the acquisition of a VRE or a VSE infection. We also identified independent mortality predictors for all patients with enterococcal infection as well as patients with only a VRE infection.

RESULTS

A total of 142 patients with enterococcal infections (VRE and VSE) were compared to 142 in-patients not infected with Enterococcus spp. independent risk factors for a VRE infection were steroid therapy within 30 days and the presence of another infection preceding the VRE infection (aOR 15.4, 95 % CI 2.4-99.3 and 23.9, 95 % CI 3.9-1482, respectively). An independent risk factor for VSE was diabetes mellitus (aOR 5.4, 95 % CI 1.1-26.6). Based on these risk factors, we developed a risk score to be used in quantifying the risk of VRE in a patient with an enterococcal infection. Male sex and low albumin were significant risk factors for mortality in our patient cohort.

CONCLUSIONS

VRE and VSE infections have distinct risk factors that can be used to guide empiric antimicrobial therapy.

摘要

背景

耐万古霉素肠球菌(VRE)是常见的感染病原体,尤其影响重症患者,且在黎巴嫩呈上升趋势。我们旨在确定医院环境中VRE和万古霉素敏感肠球菌(VSE)感染的潜在危险因素及并发症,并识别院内死亡的危险因素。

方法

采用病例 - 病例对照研究设计,将VRE和VSE患者分为两个独立组,每组与未感染的对照组进行比较。我们还构建了二元回归模型以检测与VRE或VSE感染获得相关的危险因素。我们还确定了所有肠球菌感染患者以及仅VRE感染患者的独立死亡预测因素。

结果

共将142例肠球菌感染患者(VRE和VSE)与142例未感染肠球菌属的住院患者进行比较。VRE感染的独立危险因素是30天内使用类固醇治疗以及VRE感染前存在另一种感染(调整后比值比分别为15.4,95%置信区间2.4 - 99.3和23.9,95%置信区间3.9 - 1482)。VSE的独立危险因素是糖尿病(调整后比值比5.4,95%置信区间1.1 - 26.6)。基于这些危险因素,我们制定了一个风险评分,用于量化肠球菌感染患者发生VRE的风险。男性和低白蛋白是我们患者队列中死亡的重要危险因素。

结论

VRE和VSE感染有不同的危险因素,可用于指导经验性抗菌治疗。

相似文献

1
Clinical manifestations, characteristics, and outcome of infections caused by vancomycin-resistant enterococci at a tertiary care center in Lebanon: A case-case-control study.黎巴嫩一家三级医疗中心耐万古霉素肠球菌感染的临床表现、特征及结局:一项病例-病例对照研究
J Infect Public Health. 2023 May;16(5):741-745. doi: 10.1016/j.jiph.2023.02.023. Epub 2023 Mar 6.
2
Case-case-control study on factors associated with vanB vancomycin-resistant and vancomycin-susceptible enterococcal bacteraemia.关于与耐万古霉素的vanB型和万古霉素敏感型肠球菌菌血症相关因素的病例-病例对照研究。
BMC Infect Dis. 2014 Jun 28;14:353. doi: 10.1186/1471-2334-14-353.
3
Risk factors for enterococcal infection and colonization by vancomycin-resistant enterococci in critically ill patients.危重症患者肠球菌感染和耐万古霉素肠球菌定植的危险因素。
Infection. 2014 Dec;42(6):1013-22. doi: 10.1007/s15010-014-0678-1. Epub 2014 Aug 21.
4
Comparison of morbidity and mortality after bloodstream infection with vancomycin-resistant versus -susceptible nationwide cohort study in Denmark, 2010-2019.2010 - 2019年丹麦全国队列研究:耐万古霉素与敏感血流感染后的发病率和死亡率比较
Emerg Microbes Infect. 2024 Dec;13(1):2309969. doi: 10.1080/22221751.2024.2309969. Epub 2024 Mar 11.
5
A nationwide, multicenter, case-control study comparing risk factors, treatment, and outcome for vancomycin-resistant and -susceptible enterococcal bacteremia.一项全国性、多中心、病例对照研究,比较耐万古霉素和对万古霉素敏感的肠球菌血症的危险因素、治疗方法及预后。
Diagn Microbiol Infect Dis. 2000 Mar;36(3):145-58. doi: 10.1016/s0732-8893(99)00136-4.
6
The importance of adjusting for enterococcus species when assessing the burden of vancomycin resistance: a cohort study including over 1000 cases of enterococcal bloodstream infections.评估万古霉素耐药性负担时调整肠球菌种属的重要性:一项包括 1000 多例肠球菌血流感染病例的队列研究。
Antimicrob Resist Infect Control. 2018 Nov 14;7:133. doi: 10.1186/s13756-018-0419-9. eCollection 2018.
7
Risk factors for development of vancomycin-resistant enterococcal bacteremia among VRE colonizers : A retrospective case control study.耐万古霉素肠球菌定植者发生耐万古霉素肠球菌菌血症的危险因素:一项回顾性病例对照研究。
Wien Klin Wochenschr. 2021 May;133(9-10):478-483. doi: 10.1007/s00508-020-01733-7. Epub 2020 Sep 10.
8
Enterococcal bacteremia is associated with increased risk of mortality in recipients of allogeneic hematopoietic stem cell transplantation.肠球菌菌血症与异基因造血干细胞移植受者的死亡率增加相关。
Clin Infect Dis. 2012 Sep;55(6):764-70. doi: 10.1093/cid/cis550. Epub 2012 Jun 12.
9
Economic burden of nosocomial infections caused by vancomycin-resistant enterococci.耐万古霉素肠球菌引起的医院感染的经济负担。
Antimicrob Resist Infect Control. 2018 Jan 5;7:1. doi: 10.1186/s13756-017-0291-z. eCollection 2018.
10
The Risk Factors, Costs, and Survival Analysis of Invasive VRE Infections at a Medical Center in Eastern Taiwan.台湾东部某医学中心侵袭性 VRE 感染的危险因素、成本和生存分析。
Int J Infect Dis. 2017 Jan;54:18-24. doi: 10.1016/j.ijid.2016.11.005. Epub 2016 Nov 9.

引用本文的文献

1
The Impact of spp. in the Immunocompromised Host: A Comprehensive Review.特定物种在免疫功能低下宿主中的影响:全面综述。 (注:原文中“spp.”表示“species”复数形式的缩写,这里可理解为“特定物种”,但仅从这简短原文看指代不太明确,正常情况下应该明确指出是哪些物种)
Pathogens. 2024 May 15;13(5):409. doi: 10.3390/pathogens13050409.